Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: A cost-effectiveness analysis

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue 11-12, 2007, Pages 1509-1520

  Kaplan, G G ^a,b   Hur, C ^a,b,c   Korzenik, J ^a,b   Sands, B E ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Institute for Technology Assessment   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; INFLIXIMAB;

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; CROHN DISEASE; DOSE RESPONSE; DRUG COST; DRUG DOSE ESCALATION; DRUG RESPONSE; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; REMISSION; SCORING SYSTEM; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; ANTIBODIES, MONOCLONAL; COST-BENEFIT ANALYSIS; CROHN DISEASE; DECISION SUPPORT TECHNIQUES; HEALTH CARE COSTS; HUMANS; QUALITY-ADJUSTED LIFE YEARS;

EID: 36549063053     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03548.x     Document Type: Article

References (32)

1. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999 340 : 1398 405.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomized trial. Lancet 2002 359 : 1541 9.
3. Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004 99 : 91 6.
4. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005 128 : 862 9.
5. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003 348 : 601 8.
6. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM Trial. Gastroenterology 2007 132 : 52 65.
7. Barthel HR, Gille T, Halbsguth A, Kramer M. Successful treatment with adalimumab in infliximab-resistant Crohn's disease. J Gastroenterol Hepatol 2005 20 : 1464 5.
8. Papadakis KA, Shaye OA, Vasiliauskas EA, et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005 100 : 75 9.
9. Sandborn WJ, Hanauer S, Loftus EV Jr., et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004 99 : 1984 9.
10. Stallmach A, Giese T, Schmidt C, Meuer SC, Zeuzem SS. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case. Eur J Gastroenterol Hepatol 2004 16 : 627 30.
11. Youdim A, Vasiliauskas EA, Targan SR, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004 10 : 333 8.
12. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab rapidly induces clinical remission and response in patients with moderate to severe Crohn's disease who had secondary failure to inflixmab therapy: results of the GAIN study. Am J Gastroenterol 2006 101 : S408 (A1147).
13. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976 70 : 439 44.
14. Sands BE, Steinhart AH, Lewis JD, Hanauer SB, Persson T, Sandborn WJ. Optimal Crohn's disease activity index (CDAI) response criteria is defined by decrease ≥100 points. Gastroenterology 2003 124 : A206.
15. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004 126 : 402 13.
16. Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol 2006 4 : 1017 24 quiz 976.
17. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999 117 : 49 57.
18. Gregor J, McDonald W, Klar N, et al. An evaluation of utility measures in Crohn's disease. Inflamm Bowel Dis 1997 3 : 265 76.
19. 2006 Drug Topics, Red Book. Montvale, NJ : Medical Economics, 2006.
20. AMA Website. Available at: http://www.ama-assn.org, accessed on 15 December 2006.
21. U.S. Department of Labour Bureau of Labor Statistics Data. Available at: http://www.bls.gov, accessed on 22 January 2007.
22. Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 2002 22 : 417 30.
23. Corman S, Issa M, Beaulieu DB, et al. Escalation of inflixmab maintenance therapy in Crohn's disease. Am J Gastroenterol 2006 101 : S470.
24. Regueiro M, Siemanowski B, Kip KE, Plevy S. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis 2007 13 : 1093 9.
25. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000 118 : 1018 24.
26. Azimi NA, Welch HG. The effectiveness of cost-effectiveness analysis in containing costs. J Gen Intern Med 1998 13 : 664 9.
27. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations CMAJ 1992 146 : 473 81.
28. Arseneau KO, Cohn SM, Cominelli F, Connors AF Jr. Cost-utility of initial medical management for Crohn's disease perianal fistulae. Gastroenterology 2001 120 : 1640 56.
29. Vader JP, Froehlich F, Juillerat P, et al. Appropriate treatment for Crohn's disease: methodology and summary results of a multidisciplinary international expert panel approach - EPACT. Digestion 2006 73 : 237 48.
30. Jaisson-Hot I, Flourie B, Descos L, Colin C. Management for severe Crohn's disease: a lifetime cost-utility analysis. Int J Technol Assess Health Care 2004 20 : 274 9.
31. Ollendorf DA, Lidsky L. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting. Am J Ther 2006 13 : 502 6.
32. Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II Trial. Gut 2007 56 : 1232 9.